About this Research Topic
Now that the COVID-19 pandemic is dramatically increasing with a huge amount of new SARS-CoV-2 infected people, we urge effective therapeutics and treatment protocols that are cost-effective and ready to use. To date, a lot of research and development has been performed by the scientific community to identify and test COVID-19 therapies. Methods and processes for rapidly identifying and prioritizing drugs and treatment protocols have been developed and tested. Clinical research, repurposed drug identification and testing, ongoing therapies and pathogenic mechanisms evidencing targets for pharmacological intervention have been shared within the scientific community. It is now necessary to filter and evidence available therapies ready to use to follow a common pharmacological direction.
The goal of this special issue is to develop a published resource summarizing an up-to-date collection of drugs, testing processes and results available to enable medical caregivers and hospitals to fight COVID-19 disease, and to summarize the pharmacological and clinical data supporting use. To reach this goal different approaches can be used, starting from clinical trials analysis, repurposed drugs identified and pathogenic mechanisms evidencing targets for pharmacological intervention. All of these types of information may help physicians to better define the therapies they are already performing, and to identify new strategies that may yield improvements in standard of care, and to help create or disseminate shared pharmacological interventions and treatment protocols.
Reviews, original research articles, brief research reports, case or case series/cohort reports, clinical trial reports, Letters describing relevant hypotheses (particularly relating to disease processes or pharmacological mechanisms of action), methods, policy and practice reviews and commentary, treatment protocol comparisons and reviews, and summaries of toxicology/ADMET/drug interaction considerations are welcome.
The team of Topic Editors are interested in receiving work related but not limited to the following areas:
· Clinical trials
· Ongoing trials (such as platform trials, endpoints, predictive outcome correlates and algorithms, statistical considerations)
· Clinical study reports (case series through meta-analyses)
· Repurposed drugs (discovery, screening, priority ranking and triage for clinical testing, systems biology approaches
· Ongoing therapies (efficacy analyses, risk/benefit, use in disease stages or subsets)
· Pathogenic mechanisms (systems biology, bioinformatics, meta-analyses)
· Molecular targets for pharmacological intervention (in vitro/in vivo investigations, molecular docking analyses, disease pathways)
· COVID-19 disease subsets (mild-moderate, long COVID, renal, cardiac, GI, neuropsychiatric etc.)
Topic Editor Dr. Malone is a consultant to MIT Lincoln Laboratories, Chrysalis, Evergreen, US DoD/DTRA, Leidos and Quantum Leap Healthcare Collaborative. Topic Editor Dr. Haimes is employed by SAIC (Science Applications International Corporation) and is a consultant for US DoD/ DTRA. All other Topic Editors declare no competing interests.
Keywords: Drug re-purposing, COVID-19, SARS-CoV-2, anti-inflammatory, anti-viral, histamine, clinical research
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.